Lupin is a global pharmaceutical company offering a wide range of products including branded and generic formulations, Active Pharmaceutical Ingredients (APIs), biotechnology products and speciality (UK) medicines.
With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Novel drug discovery and development in oncology, immunology and metabolic disorders, partnering with global pharma companies like Abbvie and Boehringer in novel drug development.
Lupin has a significant presence in the therapy areas of Gynaecology, Cardiovascular, Diabetes, Asthma, Paediatrics, Central Nervous System (CNS), Gastrointestinal (GI), Anti-Infective (AI) and Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs).
1. https://www.lupin.com/wp-content/uploads/2020/05/lupin-q4fy20-investor-presentation.pdf LUPIN Limited Investor Report FY2020 (Accessed Online: 3rd July 2020).
LUP-CORP-005s DOP: October 2020
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.